Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America

Peter G. Kremsner; Rodolfo Andrés Ahuad Guerrero; Eunate Arana; Gustavo Jose Aroca Martinez; Marc J.M. Bonten; Reynaldo Chandler; Gonzalo Corral; Eddie Jan Louis De Block; Lucie Ecker; Julian Justin Gabor; Carlos Alberto Garcia Lopez; Lucy Gonzales; María Angélica Granados González; Nestor Gorini; Martin P. Grobusch; Adrian D. Hrabar; Helga Junker; Alan Kimura; Claudio F. Lanata; Clara Lehmann; Isabel Leroux-Roels; Philipp Mann; Michel Fernando Martinez-Reséndez; Theresa Ochoa; Carlos Alberto Poy; Maria Jose Reyes Fentanes; Luis Maria Rivera Mejia; Vida Veronica Ruiz Herrera; Xavier Sáez-Llorens; Oliver Schönborn-Kellenberger; Mirjam Schunk; Alexandra Sierra Garcia; Itziar Vergara; Thomas Verstraeten; Marisa Vico; Lidia Oostvogels; HERALD Study Group

SSRN Electronic Journal (2021) - Comments
doi: 10.2139/ssrn.3911826 issn: 1556-5068

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana, Gustavo Jose Aroca Martinez, Marc J.M. Bonten, Reynaldo Chandler, Gonzalo Corral, Eddie Jan Louis De Block, Lucie Ecker, Julian Justin Gabor, Carlos Alberto Garcia Lopez, Lucy Gonzales, María Angélica Granados González, Nestor Gorini, Martin P. Grobusch, Adrian D. Hrabar, Helga Junker, Alan Kimura, Claudio F. Lanata, Clara Lehmann